Presentation Information

[D3-A2-03]Key considerations in biodistribution evaluation of gene therapy products using adeno-associated virus vectors

*Miyu Nakayama1 (1. Takeda Pharmaceutical Company Limited)

Password required to view


Comment

To browse or post comments, you must log in.Log in